Compares how quickly something (such as a flare, operation or death) happens over time in one group compared with another. Below 1 means it happens less often or later.
The Lancet Gastroenterology & HepatologyStudyOct 2020Patients and professionals
A longer look back at the people in the LIR!C trial. It supported keyhole removal of the end of the small bowel as a real option for people with short, mainly inflamed (not narrowed) disease when standard medicines have not worked. In both groups, adding an immunosuppressant was linked to the benefit lasting longer.
Alimentary Pharmacology & TherapeuticsDataMay 2020Patients and professionals
Using UK GP records from 2000 to 2017, this study found Crohn's became more common, rising from about 220 to 400 per 100,000 people. It predicted about 1 in 90 people in the UK would have IBD by 2025. Colitis was linked to a higher risk of bowel cancer, and both conditions to a somewhat higher risk of death than people without IBD.
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.